Rob Hopfner, Pivotal bioVenture Partners managing general partner (Credit: Pivotal Life Sciences)
VC firm Pivotal closes second $389M therapeutics fund to create companies and back public biotechs
Pivotal bioVenture Partners Fund II has fully closed at $389 million, and the Bay Area firm still has more than 75% of that funding to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
